Shares of ProMIS Neurosciences jumped 12.7% to $13.21 after Chardan initiated coverage with a Buy rating and a $20 price target, snapping a brutal five-session slide that had dragged the stock from $14.49 to $11.72. The bounce gives investors breathing room, but the real question is whether analyst enthusiasm can carry a clinical-stage company that has never earned a dollar of revenue through its most pivotal months yet.
• Wall Street Is Piling On Bullish Calls, But the Stock Keeps Falling Chardan is only the latest in a parade of Buy ratings. Seven brokerages now cover ProMIS, with a consensus "Moderate Buy" rating and an average 12-month price target of $24.00 — three analysts rate it a Buy, two rate it a Strong Buy, one a Hold, and one a Sell.
Roth Capital initiated at Buy with a $19 target in early July , and HC Wainwright reiterated Buy at $18. Yet even with this wall of support, the stock trades 67% below the $39.75 high it reached within the past year. ProMIS has a 52-week range of $6.27 to $39.75 — extreme volatility typical of micro-cap biotechs where sentiment swings can dwarf fundamentals.
• The Make-or-Break Alzheimer's Data Readout Is Weeks Away ProMIS's entire investment case hinges on its lead Alzheimer's drug, an antibody designed to target toxic protein clumps in the brain while avoiding the dangerous brain swelling seen with some approved competitors. The Phase 1b trial enrolled 144 patients, and a blinded six-month interim analysis — covering safety and biomarker trends — is expected in early Q3 2026.
Full unblinded results are expected in early Q1 2027. That interim readout, likely just weeks away, will be the single biggest catalyst for the stock this year.
• The Cash Cushion Is Solid — For Now
ProMIS closed a major financing deal with potential proceeds up to $175 million, collecting roughly $75.5 million upfront. The company held $63.8 million in cash at quarter-end, expected to fund operations through 2027.
Quarterly operating expenses ran $8.6 million, with $7.0 million going to research. That burn rate means the company won't need to raise again before its key data arrives — but a disappointing readout could make future fundraising far more expensive.
• Revenue Is Still Zero, and the EPS Trend Is Ugly
ProMIS reported a Q1 loss of $1.26 per share, missing estimates by $0.20.
Analysts project a full-year loss of roughly $5.19 per share. With no product on the market and years of trials ahead even in a best-case scenario, today's bounce is a bet on data, not earnings — and in biotech, that bet can pay off spectacularly or collapse overnight.